Optimal Effective Local Anesthetic Volume for Pain Relief Using Brachial Plexus Block
NCT ID: NCT05868993
Last Updated: 2023-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
150 participants
INTERVENTIONAL
2023-02-17
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Supraclavicular, Suprascapular, and Interscalene Nerve Blocks for Outpatient Shoulder Surgery
NCT02287142
Pulmonary Function and Interscalene Block
NCT02181296
Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery
NCT02713230
The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane
NCT03533452
Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty
NCT05005260
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Brachial Plexus Block Group 1
Interscalene
Dose of 0.5% Ropivacaine
Dose varied by 5mL of 0.5% Ropivacaine
Brachial Plexus Group 2
Supraclavicular
Dose of 0.5% Ropivacaine
Dose varied by 5mL of 0.5% Ropivacaine
Brachial Plexus Group 3
Suprascapular
Dose of 0.5% Ropivacaine
Dose varied by 5mL of 0.5% Ropivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dose of 0.5% Ropivacaine
Dose varied by 5mL of 0.5% Ropivacaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I-III
* BMI\<40
* Age \>18
Exclusion Criteria
* Inability to complete consent process in English
* allergy to ropivacaine
* neuropathy
* contraindications to peripheral nerve block per ASRA guidelines
* chronic opioid use
* infection at the injection/catheter site
* limb restriction due to medical history
* history of moderate - severe lung disease.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benaroya Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Mason Medical Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB20-018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.